文献速递烧伤创面修复

脂质体布比卡因用于刃厚皮片供区:随机对照试验

Evaluation of Liposomal Bupivacaine at Split-Thickness Skin Graft Donor Sites Through a Randomized, Controlled Trial.
PubMed 文献 · J Burn Care Res · 2021-01-01

该随机对照试验纳入成人急性烧伤(TBSA<20%)患者,每组25例,比较脂质体布比卡因与稀释利多卡因在刃厚皮片供区浸润的疗效。结果显示两组在术后疼痛评分、阿片类药物消耗量及住院时间上均无统计学差异,且均无不良事件发生。

要点

  • 脂质体布比卡因未改善供区疼痛评分。
  • 两组阿片类药物消耗量无显著差异。
  • 住院时间与不良事件发生率两组相当。

核心结论

  • 与标准利多卡因浸润相比,脂质体布比卡因用于刃厚皮片供区在疼痛控制、阿片类药物使用或住院时间方面无统计学获益。

研究设计与样本

  • 平行随机对照试验,纳入成人急性烧伤且TBSA<20%患者,每组25例;对照组供区皮下浸润稀释利多卡因,试验组浸润稀释脂质体布比卡因。

主要发现

  • 两组均无不良事件发生。

临床怎么用

  • 对于TBSA<20%的急性烧伤患者,刃厚皮片供区浸润脂质体布比卡因并未显示优于标准利多卡因,临床决策时可考虑标准方案。

局限性

  • 样本量较小(每组25例),可能不足以检测微小差异。
  • 研究人群限于TBSA<20%的急性烧伤患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Split-thickness skin grafts (STSG) are commonly required in reconstructive surgery but may cause significant pain. The goal of this investigator-initiated trial is to evaluate the effect of liposomal bupivacaine on donor site pain and opioid consumption. A parallel, randomized, controlled trial of adult acute burn patients with <20% TBSA burns was conducted to evaluate the efficacy of liposomal bupivacaine at STSG donor sites. The control group received standard subcutaneous infiltration of dilute lidocaine solution at the STSG donor site, and the experimental group received dilute liposomal bupivacaine infiltration in a similar fashion. Donor site pain scores and opioid consumption in morphine equivalents (MEE) were evaluated. A total of 25 patients were enrolled in each group. There were no statistical differences in demographic variables, and TBSA was 4.0% in both groups (P = .94). There were no statistical differences in pain scores at any time point postoperatively (mean control range 3.1/10-4.9/10, experimental range 3.3/10-4.3/10, P = .12-.96). There were no statistical differences in opioid consumption at 24, 48, or 72 h postoperatively between the groups (mean control MEE range 49.3-71.1, experimental MEE range 63.6-75.8, P = .34-.85). The average length of stay was 7.7 days in both groups (P = .88). No adverse events occurred in either group. There is no statistical benefit to the use of liposomal bupivacaine for infiltration at STSG donor sites compared to standard of care with respect to pain control, opioid use, or length of stay when evaluated in a randomized, controlled fashion.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Egan KG, Guest R, Sinik LM, et al. Evaluation of Liposomal Bupivacaine at Split-Thickness Skin Graft Donor Sites Through a Randomized, Controlled Trial. J Burn Care Res. 2021. PMID: 34216466. doi:10.1093/jbcr/irab129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。